Jennifer Kim1,2,3, Amy Lin4, Randy Absher1, Tanya Makhlouf1, Casey Wells3. 1. Cone Health, Greensboro, North Carolina, United States. 2. Area Health Education Center, Greensboro, North Carolina, United States. 3. University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States. 4. Nebraska Medicine, Omaha, Nebraska, United States.
Abstract
BACKGROUND: Mortality risk from chronic obstructive pulmonary disease (COPD) increases significantly in the first year after a 30-day hospital readmission. OBJECTIVE: To evaluate a comprehensive and collaborative pharmacist transitions of care service for patients hospitalized with COPD compared to usual care. METHODS: In this within-site, retrospective study, discharge counseling, medication reconciliation, medication access assistance, therapy changes, and post-discharge long-term follow-up were provided to underserved adult patients with a primary care provider at the study clinic and admitted to the affiliated hospital with a primary diagnosis of COPD exacerbation. Primary outcome was a 180-day composite of COPD-related hospitalizations and emergency department (ED) visits. Secondary outcomes were 30-, 60-, 90-, and 180-day events, costs, pharmacist interventions, time to follow-up, and pneumonia. RESULTS: Sixty-five patients were identified with a total of 101 index admissions. The mean age was 62.5 years, approximately 55.3% were female, and 67.7% were black or African American. The primary composite was significantly lower in the pharmacist intervention group compared to usual care (mean difference 0.82, P=0.0364, 95% confidence interval [CI] 0.05-1.60), driven by lower 30-day hospitalizations in the intervention group (mean difference 0.15, P=0.0099, 95% CI 0.04-0.27). Cost associated with COPD-related hospitalizations was significantly lower in the pharmacist intervention group compared to usual care ($173,808, P = 0.0330) as well as before intervention ($79,662, P=0.0233). There was no significant difference in time to follow-up or pneumonia. CONCLUSIONS: A comprehensive, collaborative pharmacist transitions of care service significantly reduced 30-day COPD-related hospital readmissions, ED re-visits, and associated costs in an underserved population. JCOPDF
BACKGROUND: Mortality risk from chronic obstructive pulmonary disease (COPD) increases significantly in the first year after a 30-day hospital readmission. OBJECTIVE: To evaluate a comprehensive and collaborative pharmacist transitions of care service for patients hospitalized with COPD compared to usual care. METHODS: In this within-site, retrospective study, discharge counseling, medication reconciliation, medication access assistance, therapy changes, and post-discharge long-term follow-up were provided to underserved adult patients with a primary care provider at the study clinic and admitted to the affiliated hospital with a primary diagnosis of COPD exacerbation. Primary outcome was a 180-day composite of COPD-related hospitalizations and emergency department (ED) visits. Secondary outcomes were 30-, 60-, 90-, and 180-day events, costs, pharmacist interventions, time to follow-up, and pneumonia. RESULTS: Sixty-five patients were identified with a total of 101 index admissions. The mean age was 62.5 years, approximately 55.3% were female, and 67.7% were black or African American. The primary composite was significantly lower in the pharmacist intervention group compared to usual care (mean difference 0.82, P=0.0364, 95% confidence interval [CI] 0.05-1.60), driven by lower 30-day hospitalizations in the intervention group (mean difference 0.15, P=0.0099, 95% CI 0.04-0.27). Cost associated with COPD-related hospitalizations was significantly lower in the pharmacist intervention group compared to usual care ($173,808, P = 0.0330) as well as before intervention ($79,662, P=0.0233). There was no significant difference in time to follow-up or pneumonia. CONCLUSIONS: A comprehensive, collaborative pharmacist transitions of care service significantly reduced 30-day COPD-related hospital readmissions, ED re-visits, and associated costs in an underserved population. JCOPDF
Authors: Edward C Portillo; Andrew Wilcox; Ellina Seckel; Amanda Margolis; Jean Montgomery; Prakash Balasubramanian; Geri Abshire; Jim Lewis; Christopher Hildebrand; Sameer Mathur; Alan Bridges; Sujani Kakumanu Journal: Fed Pract Date: 2018-11
Authors: Allison P Patton; Yifei Liu; D Matthew Hartwig; Justin R May; Jessica Moon; Steven C Stoner; Kendall D Guthrie Journal: J Am Pharm Assoc (2003) Date: 2017-04-12
Authors: Paul C Walker; Steven J Bernstein; Jasmine N Tucker Jones; John Piersma; Hae-Won Kim; Randolph E Regal; Latoya Kuhn; Scott A Flanders Journal: Arch Intern Med Date: 2009-11-23